Introduction
The treatment of pseudogout uses anti-inflammatory medications, joint aspiration, and longer-term management of contributing metabolic problems to reduce crystal-driven inflammation in the affected joint. Pseudogout, also called calcium pyrophosphate deposition disease (CPPD), is caused by the accumulation of calcium pyrophosphate crystals in cartilage and joint spaces. When these crystals are shed into the synovial fluid, they trigger an acute inflammatory response that produces pain, swelling, warmth, and reduced joint motion. Treatment is therefore aimed not at dissolving the crystals directly in routine practice, but at suppressing the inflammatory response they provoke, reducing joint fluid pressure, and correcting related conditions that may increase crystal formation or recurrent attacks.
Management is chosen according to the intensity of symptoms, the number of joints involved, the patient’s medical background, and whether attacks are isolated or recurrent. Some approaches are designed for rapid symptom control during an acute flare, while others focus on preventing repeated episodes and preserving joint function over time. The overall goal is to calm the immune response, restore movement, and lower the likelihood of future inflammation.
Understanding the Treatment Goals
The immediate goal in pseudogout is to reduce inflammation in the affected joint. Crystal shedding activates innate immune cells, especially neutrophils, which release inflammatory mediators and enzymes that amplify pain and swelling. By interrupting this inflammatory cascade, treatment reduces tissue irritation and helps the joint recover function.
A second goal is to address the biological context in which crystal deposition occurs. Pseudogout is more common in older adults and is associated in some cases with metabolic disturbances such as hemochromatosis, hyperparathyroidism, hypomagnesemia, and hypophosphatasia. When such conditions are present, treatment may aim to reduce the background tendency toward crystal deposition or recurrence.
Longer-term goals include preventing repeated attacks, preserving cartilage and joint mobility, and reducing complications such as persistent synovitis or progressive degenerative change. Treatment decisions are therefore guided by whether the condition is an isolated flare, a recurrent inflammatory pattern, or part of chronic CPPD arthropathy.
Common Medical Treatments
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat acute pseudogout because they reduce prostaglandin production through cyclooxygenase inhibition. Prostaglandins contribute to vasodilation, vascular permeability, and pain signaling in inflamed tissue. By limiting these pathways, NSAIDs reduce swelling and discomfort in the affected joint. Their effect is symptomatic rather than crystal-removing, but they directly target the inflammatory biology responsible for the flare.
Colchicine is another standard medication, especially useful when started early in an attack or used in low-dose prevention for recurrent flares. Colchicine binds to tubulin and interferes with microtubule formation, which impairs neutrophil migration, activation, and degranulation. Since pseudogout inflammation depends heavily on neutrophil recruitment to crystal-laden synovial fluid, colchicine reduces the cellular response that drives pain and swelling. It does not eliminate the calcium pyrophosphate crystals, but it makes the immune system less reactive to them.
Corticosteroids are often used when NSAIDs or colchicine are not suitable, or when inflammation is severe. They can be given orally or injected directly into the joint. Corticosteroids suppress multiple inflammatory pathways by altering gene transcription, reducing cytokine production, decreasing leukocyte trafficking, and stabilizing cellular responses within inflamed tissue. This broad anti-inflammatory effect is useful because pseudogout flares are mediated by cytokine-driven synovitis. Intra-articular steroid treatment is especially effective when the inflammation is confined to one joint, as it concentrates the anti-inflammatory effect where the crystal reaction is occurring.
In some cases, joint aspiration is performed as both a diagnostic and therapeutic measure. Removing synovial fluid can lower intra-articular pressure, which reduces pain and improves motion. Aspiration also removes inflammatory fluid containing crystals and activated immune cells, which may lessen the intensity of the flare. Although aspiration does not remove all crystals from the cartilage, it can interrupt the inflammatory environment inside the joint.
For people with recurrent disease, low-dose colchicine prophylaxis or intermittent anti-inflammatory treatment may be used to blunt future flares. The underlying principle is that recurrent crystal shedding can repeatedly activate the same innate immune pathways, so reducing the responsiveness of those pathways may lower flare frequency.
Procedures or Interventions
Procedural treatment is mainly centered on arthrocentesis, the removal of synovial fluid from the affected joint using a needle. This is typically used when a joint is markedly swollen, when the diagnosis is uncertain, or when infection must be excluded. The fluid can be examined for calcium pyrophosphate crystals under polarized light microscopy, which helps distinguish pseudogout from gout and from septic arthritis. Biologically, aspiration decreases the volume of inflammatory fluid and therefore the mechanical pressure on the synovial membrane and joint capsule.
Intra-articular corticosteroid injection is often performed after aspiration if infection has been ruled out. Delivering the steroid directly into the joint means the medication acts locally on synovial tissue, where it suppresses immune-cell activity and inflammatory mediator release. This approach is particularly useful in monoarticular pseudogout because it provides strong local anti-inflammatory action with less systemic exposure than oral steroids.
Surgical procedures are not commonly used to treat acute pseudogout itself. However, if chronic CPPD arthropathy leads to substantial structural damage, deformity, or severe secondary osteoarthritis, orthopedic interventions may be considered for the resulting joint dysfunction rather than for crystal deposition alone. These procedures address the mechanical consequences of long-standing inflammation and cartilage injury rather than the immediate inflammatory flare.
Supportive or Long-Term Management Approaches
Long-term management focuses on reducing the conditions that favor crystal formation and recognizing recurrent inflammation early. Because pseudogout is often associated with aging cartilage and certain metabolic abnormalities, clinicians may evaluate for contributing disorders such as calcium, magnesium, iron, phosphorus, parathyroid, and thyroid abnormalities. When a secondary cause is found, treating that disorder can alter the biochemical environment that contributes to crystal deposition or recurrent synovitis.
Ongoing follow-up is used to distinguish isolated flares from chronic CPPD disease. Repeated attacks can lead to cumulative synovial irritation and gradual functional decline, so monitoring helps identify when recurrent inflammation is becoming a longer-term joint disease. Imaging may show chondrocalcinosis, joint-space narrowing, or degenerative changes, which reflect the structural impact of persistent crystal-related inflammation.
Supportive management also includes maintaining joint mobility and minimizing prolonged inflammation. The biological rationale is that inflamed synovium and prolonged immobility can promote stiffness, reduced muscle support, and impaired joint mechanics. In chronic disease, treatment often combines anti-inflammatory control with measures aimed at preserving function and reducing the downstream effects of recurrent synovitis.
Factors That Influence Treatment Choices
Treatment varies according to the severity of the flare. A mild attack in one joint may respond to local measures such as aspiration and intra-articular steroid injection, while severe or widespread inflammation may require systemic treatment with NSAIDs, colchicine, or oral corticosteroids. The extent of joint involvement matters because the inflammatory burden is greater when multiple joints are affected, and local therapy may not be sufficient in that setting.
Age and general health strongly influence treatment selection. Older adults are the most commonly affected group, and they often have kidney disease, cardiovascular disease, gastrointestinal vulnerability, or drug interactions that limit the safe use of NSAIDs or colchicine. These factors matter because the same anti-inflammatory mechanism that helps the joint can also affect other organs. Corticosteroids may be favored in some medically complex patients because they can be used when other agents are less tolerable, although they bring their own systemic effects.
Underlying metabolic disorders also shape treatment choices. If pseudogout is associated with hyperparathyroidism or hypomagnesemia, management may include correction of those abnormalities to reduce the biochemical tendency toward further crystal deposition. Previous response to therapy matters as well: patients with repeated flares despite acute treatment may need preventive colchicine or reassessment for chronic CPPD arthropathy. The choice of treatment reflects whether the main problem is acute inflammation, recurrent inflammatory activation, or structural joint damage.
Potential Risks or Limitations of Treatment
The major limitation of standard pseudogout treatment is that it controls inflammation without removing established calcium pyrophosphate crystals from cartilage in a rapid or reliable way. As a result, attacks can recur if the crystal burden remains and the joint continues to shed crystals into synovial fluid. Treatment is therefore suppressive rather than curative in most cases.
Each medication class has specific risks related to its mechanism. NSAIDs can reduce protective prostaglandins in the stomach and kidneys, which may lead to gastrointestinal irritation, bleeding risk, fluid retention, or impaired renal function. These effects arise because prostaglandins also support mucosal defense and renal blood flow. Colchicine can cause gastrointestinal upset and, at higher exposures or in patients with impaired clearance, may lead to toxicity affecting muscle, blood cells, or nerve function. Its narrow therapeutic window reflects the fact that microtubules are important in many cell types, not only inflammatory cells.
Corticosteroids can produce hyperglycemia, fluid retention, mood changes, and other systemic effects when used orally or repeatedly. Even when injected into a joint, there is some risk of transient local pain, and injections should be avoided if joint infection is a possibility. Arthrocentesis carries a small procedural risk of bleeding, pain, or introduction of infection, though it is generally safe when performed properly.
Another limitation is that chronic CPPD arthropathy may overlap clinically with osteoarthritis or other inflammatory joint disorders. Because the crystal process can coexist with mechanical degeneration, symptom relief may be incomplete if only the acute inflammation is treated and the underlying joint damage has already progressed.
Conclusion
Pseudogout is treated by reducing the inflammatory response to calcium pyrophosphate crystals, relieving joint pressure, and addressing metabolic or structural factors that contribute to recurrence. NSAIDs, colchicine, and corticosteroids work through different anti-inflammatory mechanisms, but all are aimed at suppressing the neutrophil-driven synovitis that causes pain and swelling. Joint aspiration can both confirm the diagnosis and reduce inflammatory fluid within the joint, while injections deliver medication directly to the inflamed synovium. Longer-term management focuses on recurrent disease, associated metabolic abnormalities, and preservation of joint function. The overall treatment strategy is therefore built around the biology of crystal-induced inflammation and the mechanical consequences of repeated synovial injury.